Migraine
Conditions
Interventions
Experimental Group:Transcetaneous Electrical Stimulation
Ctrl Group:Fake Stimulus
Sponsors
The Second Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, aged between 18 and 75; 2. According to the diagnostic criteria of the International Classification of Headache Disorders (ICHD-III), the diagnosis is episodic migraine with or without aura or probable migraine with or without aura;3. The duration of the illness is at least 12 months; 4. The age of onset of the first migraine is less than 50 years old; 5. During the screening period of 4 weeks, there were 2-8 episodes of headache, with moderate or severe pain intensity;- 6. Before screening, the subjects should provide their previous medical records as much as possible; 7. Participants can distinguish migraines from other conditions, including tension-type headaches and cluster headaches 8. Understand and adhere to the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating women; 2. Suffering from arrhythmia or other heart diseases (such as ischemic heart disease, coronary artery spasm, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, angina pectoris); 3. Have undergone surgery within the past 6 months; 4. Recent stroke or transient ischemic attack 5. Equipped with a pacemaker; 6. History of previous seizures; 8. Metal implants in the head; 9. Patients with clinical evidence of brain damage; 10. Chronic pain associated with other diseases; 11. Use antipsychotic drugs; 12. Those who are intolerant to neuroregulators; 13. Employees of the research center or their immediate family members. 14. There is a condition or anomaly that the investigator believes may affect patient safety or data quality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Two hours after treatment, the participants' headache intensity score was 0 (no pain = 0 points, mild = 1 point, moderate = 2 points, severe = 3 points).;Two hours after the treatment, the participants no longer experienced the pre-selected accompanying symptoms (such as nausea, vomiting, photophobia, phonophobia, etc.).; | — |
Secondary
| Measure | Time frame |
|---|---|
| Two hours after treatment, the participants' pain was relieved (from moderate to severe pain to mild pain).;After 2 hours of treatment, the participants' functions returned to normal;The use of acute therapeutic drugs within 24 hours after treatment;There were no recurrent migraine attacks within 2 to 24 hours after the treatment.;There were no recurrent migraine attacks within 2 to 48 hours after the treatment.;After the treatment, at 15, 30, 45, 60 and 90 minutes, the participants' pain levels changed from moderate to severe to completely pain-free (the VAS score became 0).;After the treatment, the accompanying symptoms (such as nausea, vomiting, photophobia, and phonophobia) of the participants no longer occurred at 15, 30, 45, 60, and 90 minutes.; | — |
Countries
China
Contacts
Public ContactKaiming Liu
The Second Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed